WO2000027885A1 - Nouveau popypeptide chimerique - Google Patents

Nouveau popypeptide chimerique Download PDF

Info

Publication number
WO2000027885A1
WO2000027885A1 PCT/JP1999/006152 JP9906152W WO0027885A1 WO 2000027885 A1 WO2000027885 A1 WO 2000027885A1 JP 9906152 W JP9906152 W JP 9906152W WO 0027885 A1 WO0027885 A1 WO 0027885A1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
closo
closoprotein
human
dna
Prior art date
Application number
PCT/JP1999/006152
Other languages
English (en)
Japanese (ja)
Inventor
Nobuo Hanai
Kazuyasu Nakamura
Yukinari Kato
Youichi Nabeshima
Original Assignee
Kyowa Hakko Kogyo Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co., Ltd. filed Critical Kyowa Hakko Kogyo Co., Ltd.
Priority to AU10772/00A priority Critical patent/AU1077200A/en
Publication of WO2000027885A1 publication Critical patent/WO2000027885A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Definitions

  • the present invention relates to a chimeric polypeptide in which a closoprotein and an immunoglobulin are bound, a DNA encoding the chimeric polypeptide, a method for producing the chimeric polypeptide, a DNA encoding the chimeric polypeptide or the chimeric polypeptide.
  • the Klotho gene is located at the site of transgenic mouse insertion in a transgenic mouse that exhibits remarkable and various premature aging symptoms, such as shortened life span, calcification of various organs, arteriosclerosis, and atrophy of reproductive organs. It is a gene identified as a causative gene for aging symptoms [Nature, 390, 45 (1997)].
  • the human closogene has also been cloned using the mouse closogene, and its structure has been elucidated.
  • one of the closoproteins is a type 1 membrane protein (hereinafter referred to as a “type 1 membrane protein” having a structure having an N-terminal signal sequence region, an extracellular domain region, and a C-terminal transmembrane domain region).
  • the cell-domain I is composed of two domains (KL1, KL2) that are homologous to bacterial or plant ⁇ -glucosidase.
  • the other protein is a secretory protein having a signal sequence region at the N-terminal and a KL1 domain region (hereinafter referred to as a secretory protein). GBiochem. Biophys. Res. Commun., 242, 626 (1998)].
  • Lys Lys Arg Lys an amino acid sequence commonly found in sites that are cleaved by peptide hormone precursors, etc., is recognized. It has been suggested that the KL1 domain may be secreted following cleavage of the ligated closoprotein after translation.
  • the expression of the Kokuso gene is high in the kidney, the severe aging symptoms caused by the Kokuso gene mutation affect systemic organs including the lungs, bones, stomach wall, and skin. It is presumed that some secretory factor s exists in the mechanism and exerts its effects [Nature, 390, 45 (1997)]. However, the mechanism by which the liposomal gene mutation causes various aging symptoms—the molecular function of liposomal protein has not yet been elucidated.
  • Croso mice The aging of Croso mice has been achieved by cross-breeding experiments between Chloro // mouse and transgenic mice expressing the Closo gene, and experiments in which Closo proteins are expressed in Closo mice using an adenovirus vector incorporating membrane-bound Closo cDNA. Because of the prevention of the onset of symptoms, it is thought that the treatment of diseases caused by dysfunction of the stomatoprotein can be achieved by expressing the closo gene in the patient's body by gene therapy [Nature, 390, 45 (1997), W098 / 29544). However, by administering directly from outside the Klotho ⁇ white matter, no report about whether the treatment or prevention force? Possible of such diseases.
  • closoproteins such as membrane-bound closoprotein, secreted closoprotein, and closoprotein having only the KL1 region are administered from the outside, and the therapeutic or preventive effects of the above-mentioned diseases are analyzed, whereby the activity of the closoprotein is improved. It is thought that important areas can be analyzed.
  • a method of administering such a biological activity and a desired protein to a living body a method of administering the protein directly into the blood by a technique such as intravenous injection is common. Shin power shin power?
  • the administered bioactive 5 ′ expected protein is cleared by the kidney glomerulus. Due to clearance and degradation by proteases in the blood, the half-life in the blood is shortened, and the desired effect may not be expected.
  • the constant region of the immunoglobulin to be bound includes a light chain (CL) and a heavy chain (consisting of a CH1-hinge-CH2-CH3 domain).
  • CL light chain
  • heavy chain consisting of a CH1-hinge-CH2-CH3 domain.
  • the domain below the hinge excluding the CH1 domain of the heavy chain for the following reasons: It is commonly used.
  • the hinge portion has a flexible structure, and it is highly likely that the binding of the foreign protein at the hinge portion can maintain the activity of the foreign protein and immunoglobulin without impairing the original three-dimensional structure [Trends in Biotechnology, 14 52 (1996)].
  • a chimeric polypeptide of a closoprotein and an immunoglobulin is expressed in animal cells by a gene recombination technique, and the purified chimeric polypeptide is administered to a closo mouse or a model animal of various diseases, whereby the disease model animal
  • the present inventors have completed the present invention by confirming that the symptom is improved.
  • the present invention provides the following (1) to (24).
  • a chimeric polypeptide in which immunoglobulin is bound to a closoprotein (1) A chimeric polypeptide in which immunoglobulin is bound to a closoprotein.
  • chimeric polypeptide according to any one of (1) to (7) above, wherein the chimeric polypeptide is a chimeric polypeptide in which an immunoglobulin is bound via a linker peptide to the C-terminal side of a closoprotein.
  • Petit 9 a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or 4, or an amino acid sequence in which one or several amino acids have been deleted, substituted or added in the amino acid sequence of the polypeptide, and a closoprotein A polypeptide having the activity of:
  • deletion, substitution or addition of the above amino acids can be performed by the methods described in Nucleic Acids Research, 10, 6487 (1982), Proc. Natl. Acad. Sci “USA, 79, 6409 (1982), Gene, 34, 315 (1985), Nucleic Acids. Acids Research, 13, 4431 (1985), Proc. Natl. Acad. Sci., USA, 82, 488 (1985), etc., using the site-directed mutagenesis method described in SEQ ID NO: 2 or 4. This can be done by introducing site-specific mutations into the DNA encoding the polypeptide, or one or several amino acids, as many as can be deleted, substituted, or added by site-directed mutagenesis. Means amino acid.
  • a DNA comprising a nucleotide sequence selected from the nucleotide sequences shown in SEQ ID NOs: 1, 3, 5, and 6, or a DNA that hybridizes with the DNA under stringent conditions; and DNA encoding a polypeptide having an activity.
  • the above-mentioned ⁇ DNAJ that hybridizes under stringent conditions '' refers to a colony hybridisation method, a plaque, '' It means DNA obtained by using the hybridization method or Southern blot hybridization method, and more specifically, using a filter on which DNA derived from colonies or plaques is immobilized.
  • SSC saline-sodium citrate
  • composition of 1-time concentration SSC solution DNA can be identified by washing the filter at 65 ° C using 15 mmol Zl sodium chloride and 15 mmol Zl sodium citrate). Can be given.
  • Hybridization is based on Molecular Cloning, A LABORATORY MANUAL, Second Edition, Cold Spring Harbor Laboratory Press (1989) (hereinafter abbreviated as Molecular-Cloning 2nd Edition), -Current Protocols in Molecular Biology, Supplement 1 ⁇ 38, John Wiley & Sons (1987-1997) (hereinafter abbreviated as current-protocols 'in' molecular biology sub-units 1-38, DNA and loningl: Core iechniques, A Practical Approach, Second Edition, Oxford University Press (1995) and the like.
  • hybridizable DNA examples include a DNA having at least 60% homology with the nucleotide sequence selected from the nucleotide sequences shown in SEQ ID NOs: 1, 3, 5, and 6, and preferably a homology of 80% or more. And more preferably a DNA having a homology of 95% or more.
  • (1 3) is recombinant DNA force pKA TEXKLL 7 1 or pKANTEXKLL ⁇ 4, the (1 2) recombinant DNA according.
  • transformant is a transformant selected from a microorganism, an animal cell, a plant cell, an insect cell, a non-human transgenic animal, and a transgenic plant.
  • a transformant containing a recombinant DNA obtained by incorporating a DNA encoding the polypeptide according to any one of the above (1) to (9) into a vector is used as a culture solution. And producing the polypeptide in the culture, collecting the polypeptide from the culture, and producing the polypeptide.
  • a therapeutic agent for a disease selected from renal disease, cachexia and osteoarthritis comprising the polypeptide according to any one of the above (1) to (9).
  • a preventive agent for a disease selected from renal disease, cachexia and osteoarthritis comprising the polypeptide according to any one of the above (1) to (9).
  • (21) A gene therapy vector comprising the DNA of (10) or (11) above.
  • (22) A method for detecting a molecule that interacts with a closoprotein, using the polypeptide of (1) to (9) above.
  • Closo Ig DNA coding for a chimeric polypeptide obtained by binding a closoprotein and immunoglobulin (hereinafter referred to as Closo ZIg DNA) ) Consists of the DNA encoding the closoprotein and the DNA encoding the immunoglobulin.
  • any protein may be used as long as it is a protein having the activity of Closoprotein, but a Closoprotein containing a KL1 domain and having no transmembrane domain is preferable.
  • Such closoproteins include, for example, fragments of only the extracellular domain excluding the transmembrane domain of secretory closoproteins and membrane-bound closoproteins.
  • Specific examples include secretory closoproteins derived from mouse or human, and fragments of only the extracellular domain excluding the transmembrane domain of the membrane-bound closoprotein.
  • Plasmid containing DNA encoding these proteins Specific examples of pNKH106 (FERM BP-5767) containing DNA encoding human secretory closoprotein, pNKH102 (FERM BP-5766) containing DNA encoding human membrane-bound closoprotein, mouse PNKM112 (FERM BP-6184) containing DNA encoding secretory closoprotein, and ⁇ (FERM BP-5765) containing DNA encoding mouse membrane-bound closoprotein (W098 / 29544).
  • the immunoglobulin I g G, I gM, I gA, neither I gE can be used, it mosquito?
  • the domains of the hinge one CH2 - CH3 H chain of I gG It is more preferable to use a region including the region (hereinafter, referred to as Fc region).
  • Plasmids containing DNA encoding human IgG include phBSC4 (W097 / 10354), pKANTEX93 (W097 / 10354), pBRHIGl [Nucl. Acid. Res., 10, 4071 (1982). PATHG3 [Nucl. Acid. Res.,, 1779 (1986)].
  • closo-ZI g When closo-ZI g is administered to humans as a prophylactic or therapeutic agent for diseases associated with closo-gene, human-derived closoprotein and immunoglobulin in closo / Ig can be used as anti-closo-ZIg antibodies. Is considered difficult to make, desirable.
  • DNA encoding the Closo Ig specifically, a fragment obtained by cutting pNKH106, which encodes a human secretory closoprotein, with Ec0RI and PvuII, and SacII of pKANTEX93, DNA encoding human secreted closonohuman IgG1 Fc chimeraboli peptide obtained by isolating the BamHI fragment and linking both via synthetic DNA can be mentioned.
  • the synthetic DNA includes a closoprotein which has been deleted by restriction enzyme digestion, and a DNA which encodes an amino acid sequence which complements the amino acid sequence of IgG1Fc and binds both. It is a thing.
  • the DNA fragment encoding the closoprotein or immunoglobulin should be obtained by amplifying a DNA fragment by PCR using primers corresponding to the base sequence of the portion to be amplified by converting the plasmid containing each gene into type II. Can also be prepared.
  • Chimeric polypeptides in which liposomal proteins and immunoglobulins are bound can be prepared by directly binding the N-terminus of the immunoglobulin to the C-terminus of the closoprotein portion. Changes in the three-dimensional structure of both proteins due to force binding.
  • the closoprotein and the immunoglobulin can be bound via an appropriate length peptide (hereinafter, such an appropriate length peptide is called a linker peptide).
  • Linker peptides are chimeric polypeptides of the IL-5 receptor chain and the IgG constant region [J. Biol. Chem., 268, 6581 (1993)] and the ⁇ chain variable region of single-chain antibodies. Natl. Acad. Sci. USA, 85, 5879 (1988), Nature, 339, 394 (1989)] and the length of 4 to 20 residues were used. in order group, the force used Quy glycine Ya serine to get a specific secondary structure as an amino acid? desirable.
  • DNA encoding a polypeptide signal peptide is added to the N-terminal to the [2] insert expressed base Kuta foremost, it mosquitoes? preferred to secrete expressed Kurosono I g in animal cells.
  • the signal peptide used here is closogene A signal peptide consisting of 33 amino acids which the child originally has may be used, or a signal peptide of another secreted protein such as human IgG and human growth hormone may be used.
  • Closo / Ig DNA prepared as described above can be incorporated into a plasmid vector capable of autonomous replication in a host organism for amplification and maintenance.
  • This plasmid vector has a restriction enzyme site that can easily insert a foreign gene, and can express a gene such as a drug resistance gene to select a host organism into which the vector has been introduced . Used.
  • E. coli Escherichia which is a gram-negative bacterium, is preferably used because it is easy to introduce and isolate the vector, and the host organism is easy to culture and grow quickly.
  • Plasmid vectors used in E. coli include pBluescriptll SK (-) (Stratagene) and pZErO-1 (Invitrogen)
  • the polypeptide of the present invention can be produced by obtaining the transformant and culturing the transformant.
  • An expression vector is capable of autonomous replication in a host cell or Those that are capable of integration and contain a promoter that can transcribe mRNA from Closo / Ig DNA in the host cell are used.
  • the host cell any prokaryotic cell, yeast, animal cell, insect cell, plant cell, or the like can be used as long as it can express the gene of interest. In addition, animal and plant individuals can be used.
  • closo ZIg retains the correct three-dimensional structure.
  • modification of sugar chains and the like is performed, and it is considered that they have an action similar to that of closoprotein.
  • an expression vector that contains a promoter for transcription in the host animal cell, Closo ZIg DNA, and a signal sequence for termination of transcription and polyadenylation of the transcript is used.
  • a vector capable of expressing a drug resistance gene that is capable of autonomous replication and gene transfer.
  • any promoter can be used as long as it can perform transcription in animal cells.
  • Enhancer Rous sarcoma virus (RSV), human immunodeficiency virus (HIV), Moloney mouse leukemia virus (MMLV), etc.
  • a permanent closo / Ig-expressing cell in which chroso-ZI g DNA is integrated into the host chromosomal DNA is a host cell containing a closo / g expression vector containing a sequence capable of expressing a resistance gene to a drug such as G418 or hygromycin. In the presence of drugs And can be selected by culturing.
  • a mouse / Ig constitutive expression vector containing a sequence capable of expressing the dihydrofolate reductase (dhfr) gene was prepared.
  • a host cell for performing gene amplification using the dhfr gene a cell in which the dhfr gene does not function, for example, CHO / dhfr- (ATCC: CRL-9096) is used.
  • Closo ZIg expression vector examples include, for example, pAGE107 [JP-A-3-22979, Cytotechnology, 3, 133, (1990)], pAS3-3 (special Kaihei 2-227075), pCDM8 [Nature, 329, 840, (1987)], pcDNA3.1 (+) (Invitrogen), pREP4 (Invitrogen), pBK-RSV (Stratagene), p SVK3 [Amersham Pharmacia Biotech], cDNA l / Amp (Invitrogen), pc DNA1.1 (Invitrogen), pAGE103 Q.
  • Host cells include mouse / myeloma cells such as SP2 / 0, NS0, etc., rat-myeloma cells such as YB2 / 0, etc., african green monkey kidney cells such as COS-1, COS-7, and 293 etc. Human fetal kidney cells, hamster cells such as CH0 cells, BHK spores, etc.
  • the host cell should be one that does not produce immunoglobulin by itself before the introduction of the vector. Purification of Clos Zig, and isolation is preferred.
  • any method for introducing DNA into animal cells can be used.
  • the elect-portion method [ Cytotechnology, 3, 133 (1990)]
  • calcium phosphate method Japanese Patent Application Laid-Open No. 2-227075
  • lipofection method Proc. Natl. Acad. Sci. USA, 84.7413 (1987)]
  • Bacuiovirus Express ion Vectors A Laboratory Manual , WH Freeman and Company, New York (1992), Bio / Technology, 6, 47 (1988) ] force? Used. That is, after inserting the croso-Ig DNA into a vector called a transfer vector, the vector and the baculovirus are simultaneously introduced into insect cells, and placed under the promoter of the polyhedrin gene, which is a strong promoter.
  • Closono / I Eight clones of recombinant baculovirus were prepared by homologous recombination, and the recombinant baculovirus was again infected into insect cells to express closono Ig. Can be.
  • Baculoviruses include Autographa cal i fornica nuclear polyhedrosis virus and silkworm nuclear polyhedrosis virus.
  • As insect cells Spodoptera frugiperda cells Sf9 and Sf21 [Bacuiovirus Expression Vectors, A Laboratory Manual, New York (1992)], Trichoplusia ni cells High 5 (manufactured by Invitrogen Corporation), and the like can be used. .
  • the silkworm larva can also be used as it is.
  • the transfer vector contains a polyhedrin promoter and a baculovirus-derived sequence for causing the same recombination, as well as maintenance and propagation of the vector and genetic manipulation such as integration of foreign genes in E. coli.
  • Closo ZIg can also be produced using an individual animal. For example, according to a known method [American Journal oi Clinical Nutrition, 63.639S (1996), American Journal of Clinical Nutrition, 63, 627S (1996), Bio / Technology, 9, 830 (1991)]. To produce closo / Ig in animals transfected with closo / Ig DNA. it can.
  • the promoter the force can be used, so long as it can function in an animal s, for example, non-casein promoter which is a mammary gland cell-specific promoters one
  • Any promoter that can express the gene in plant cells can be used as the promoter for the expression of Closo Ig DNA.
  • the 35S promoter of cauliflower mosaic virus (CaMV) and the inactin 1 promoter are used as the promoter for the expression of Closo Ig DNA.
  • CaMV cauliflower mosaic virus
  • inactin 1 promoter by inserting intron 1 of maize alcohol dehydrogenase gene between the promoter and the Closo ZI g DNA to be expressed, the expression efficiency of the Closo ZI g DNA can be increased. Can also be given.
  • Examples of the host cell include plant cells such as potato, tobacco, corn, rice, rape, soybean, tomato, wheat, barley, rye, Alfalpha, flax and the like.
  • any method for introducing DNA into plant cells can be used.
  • agrobacterium electroporation [Cytotechnology, 3, 133 (1990) )]
  • Particle gun a method for introducing DNA into plant cells.
  • agrobacterium electroporation [Cytotechnology, 3, 133 (1990) )]
  • Particle gun a method for introducing DNA into plant cells.
  • agrobacterium electroporation [Cytotechnology, 3, 133 (1990) )]
  • Particle gun Particle gun
  • Cells and organs of a plant into which Closo ZIgDNA has been introduced can be cultured in large quantities using a jar fermenter.
  • plant individuals (transgenic plants) into which the Closo ZIgDNA has been introduced can also be constructed.
  • Closo Ig expression vector When using a prokaryote such as a bacterium as a host cell, use a Closo Ig expression vector.
  • Is used which is capable of autonomous replication in a host prokaryote and in which closo // Ig DNA is arranged downstream of a promoter having a ribosome binding sequence. It is preferable that the distance between the ribosome binding sequence and the initiation codon is adjusted to an appropriate distance (for example, 6 to 18 bases in the case of an E. coli host vector). Although not necessary, it is better to place the transcription termination sequence directly below the Closo / 1 g DNA. In addition, for the selection of the transformant, a sequence that expresses a gene that can be the most important, such as a drug resistance gene, should be included.
  • any promoter can be used as long as it can be expressed in a host cell. If for example where the E. coli and inn production, t ⁇ promoter (Ptrp), lac pro motor-(Pi3 ⁇ 4 £), P L promoter one, T7 promoter one coater, such as [rho kappa promoter, promoters derived from Escherichia coli or phage, etc. I can give first class. Also, artificially designed and modified promoters such as a promoter (P ⁇ 2 x 2), a promoter, a T71ac promoter, and a let I promoter in which two P trps are connected in series can be used.
  • Bacillus subtilis When Bacillus subtilis is used as a host, examples thereof include promoters of SP01 and SP02 which are phages of Bacillus subtilis, pen P promoter and the like.
  • expression vectors include pSE280 (manufactured by Invitrogen), pGEMEX-1 (manufactured by Promega), pQE-8 (manufactured by QIAGEN), and pKYP10 (manufactured by Tokukai Sho 58-1) 106 000), p KYP 200 Agric. Biol. Chem., 48, 669 (1984)], p LSA 1 [Agric. Biol. Chem., 53, 277 (1989)], pGEL 1 [Proc. Natl.
  • microorganisms belonging to the genus Escherichia, Serratia, Bacillus, Brevibacterium, Corynebacterium, Microbacterium, Pseudomonas, etc. for example, Escherichia col i XLl-Blue, Escherichia col i XL2-Blue , Escherichia col i DH1, Escherichia col i MC1000> Escherichia col i—KY3276, Escherichia col i W1485, Escherichia col i 09, Escherichia col i concealed 01, Escherichia col i No.
  • Corynebacterium glutamicum ATCC140 Corynebacterium glutamicum ATCC13869, Corynebacterium acetoacidophi lum ATCC13870, Microbacterium ammoni aphi lum ATCC15354, Pseudomonas sp. D-0110 and the like.
  • Any method for introducing the recombinant vector can be used as long as it is a method for introducing DNA into the host cell described above.
  • electroporation Nucleic Acids Res., 16, 6127 (1988)), USA, 69, 2110 (1972)]
  • a protoplast method JP-A-63-248394
  • Gene 17, 107 (1982)
  • Molecular & General Genet. ics 168, 111 (1979).
  • the expression vector When yeast is used as a host cell, the expression vector includes a promoter that performs transcription in the host yeast, Crosono Ig DNA, a transcription termination sequence, and a gene that becomes a transformation marker in yeast, such as a drug resistance gene and Those containing a sequence capable of expressing an amino acid synthesis system gene such as TRP1, HIS3, LEU2, etc. are used.
  • a promoter that performs transcription in the host yeast
  • Crosono Ig DNA a transcription termination sequence
  • a gene that becomes a transformation marker in yeast such as a drug resistance gene and Those containing a sequence capable of expressing an amino acid synthesis system gene such as TRP1, HIS3, LEU2, etc. are used.
  • a gene that becomes a transformation marker in yeast such as a drug resistance gene and Those containing a sequence capable of expressing an amino acid synthesis system gene such as TRP1, HIS3, LEU2, etc. are used.
  • Any promoter can be used as long as it can perform transcription in yeast.
  • the alcohol dehydrogenase gene ADH1 of Saccha genus yces cerevisiae and the galactokinase gene GAL1 GAL10 can be used.
  • Promoter-PH05 promoter, PGK promoter, GAP promoter, heat shock protein promoter, MF ⁇ 1 promoter, CUP 1 promoter, Pichia pastor is alcohol oxidase gene A 0 X 1 promoter Etc. are used.
  • any method can be used as long as it is a method for introducing DNA into yeast, and examples thereof include an electroporation method (Methods.Enzymol. 194, 182 (1990)) and a spheroplast method [ Natl. Acad. Sci. USA, 81, 4889 (1984)], lithium acetate method [Journal of Bacteriology, 153, 163 (1983)], and the like.
  • a transformant derived from a microorganism, animal cell, or plant cell having a recombinant vector incorporating a DNA encoding the Closo ZIg of the present invention is cultured according to a conventional culture method. By producing and accumulating Closo ZIg and collecting the Closo / Ig from the culture, the Closo ZIg can be produced.
  • RPMI 1640 medium [The Journal of the American Medical Association, 199, 519 (1967)] Eag 1e MEM Medium [Science, 122, 501 (1952)] D MEM medium [Virology, 8, 396 (1959)] 1 99 Medium [Proceeding of the Society for the Biological Medicine, 73, 1 (1950)]
  • a medium or the like to which fetal serum or the like has been added can be used.
  • the fetal bovine serum because it contains immunoglobulins of cattle, it force not use if you row the isolation and purification of closo / g from the culture medium? Desirable.
  • an antibiotic such as benicillin-strebtomycin may be added to the medium.
  • an antibiotic such as kanamycin or penicillin may be added to the medium during the culture.
  • TNM-FH medium Pulsen
  • Si-900 II SFM medium Si-900 II SFM medium
  • ExCel 1400 ExCel 1400
  • EXCe 1405 All manufactured by JRH Biosciences
  • Grace's Insect Medium Grace, T., Nature, 195, 788 (1962)
  • Culture conditions are preferably pH 6-7, culture temperature 25-30 ° C, and culture time is usually 1-5 days.
  • an antibiotic such as gentamicin may be added to the medium during the culture.
  • the transformant When the transformant is an animal or plant individual, it is bred or cultivated according to a usual method to produce and accumulate the Closo ZIg of the present invention, and collect the Closo / Ig from the animal or plant individual By doing so, the Closo / Ig can be produced.
  • a non-human transgenic animal having the Closo / 7 Ig DNA of the present invention is bred, and the recombinant DNA encoding Closo / 1 g is added to the animal.
  • the Closo / Ig can be produced. Production and storage in the animal For example, milk, eggs and the like of the animal can be mentioned.
  • a transgenic plant having the Closo ZIg DNA of the present invention is cultivated, the Closo ZIg of the present invention is produced and accumulated in the plant, and the Closo / Ig is extracted from the plant. By collecting, the Closo ZIg can be produced.
  • a culture medium for culturing a transformant obtained by using a prokaryote such as Escherichia coli or a eukaryote such as yeast as a host contains a carbon source, a nitrogen source, inorganic salts, and the like which can be used by the organism. Either a natural medium or a synthetic medium can be used as long as the medium can efficiently culture the cells.
  • the carbon source may be any one that can be assimilated by the organism, such as glucose, fructose, sucrose, molasses containing these, carbohydrates such as starch or starch hydrolysate, and organic acids such as acetic acid and propionic acid. Acids, alcohols such as ethanol and propanol, and the like can be used.
  • Nitrogen sources include ammonia, ammonium chloride, ammonium sulfate, ammonium acetate, ammonium phosphate, etc., ammonium salts of inorganic or organic acids, other nitrogen-containing compounds, peptone, meat extract, yeast extract, corn starch, etc. Plyka, casein hydrolyzate, soybean meal and soybean meal hydrolyzate, various fermented cells, and digests thereof can be used.
  • potassium potassium phosphate potassium potassium phosphate, magnesium phosphate, magnesium sulfate, sodium chloride, ferrous sulfate, manganese sulfate, copper sulfate, calcium carbonate, and the like can be used.
  • the culture is usually performed under aerobic conditions such as shaking culture or deep aeration stirring culture.
  • the cultivation temperature is preferably 15 to 40 ° C, and the cultivation period is usually 16 to 96 hours.
  • the pH is maintained at 3.0 to 9.0.
  • the pH is adjusted using an inorganic or organic acid, an alkaline solution, urea, calcium carbonate, ammonia, or the like. If necessary, antibiotics such as ampicillin-tetracycline may be added to the medium during the culture period. Good.
  • an inducer may be added to the medium as necessary.
  • an inducer may be added to the medium as necessary.
  • acrylic acid or the like may be added to the medium.
  • closo / I g When it is secreted outside closo ZI g force s cells, closo / I g is it accumulated in the medium. Therefore, after the culture is completed, only the medium without cells is collected by a method such as centrifugation.
  • Normal protein isolation and purification methods from the culture medium ie, solvent extraction, salting out using ammonium sulfate, desalting, precipitation with organic solvents, getylaminoethyl (DEAE) — Cephalos, DIAI0N HPA -Anion exchange chromatography using resins such as 75 (Mitsubishi Chemical), Mono-Q (Amersham-Pharmacia's Biotech), and resins such as SP Sepharose (Amersham-Pharmacia-Biotech) Cation exchange chromatography, hydrophobic chromatography using resins such as butyl sepharose, phenyl sepharose, gel filtration using molecular sieve, affinity chromatography, chromat
  • the immunoglobulin constant region of Closo / Ig is derived from IgG, a purified sample can be easily obtained by affinity chromatography using protein A or protein G, which has the property of specifically binding to IgG. be able to.
  • the cells of the transformant are collected from the culture after the completion of the culture by centrifugation or the like, and suspended in a buffer. Crush cells with a sonicator or French press to obtain a cell-free extract.
  • Closo Ig of the present invention can also be produced by a chemical synthesis method such as the Fmoc method (fluorenylmethyloxycarbonyl method) and the tB0c method (t-butyloxycarbonyl method). can do.
  • a chemical synthesis method such as the Fmoc method (fluorenylmethyloxycarbonyl method) and the tB0c method (t-butyloxycarbonyl method).
  • Fmoc method fluorenylmethyloxycarbonyl method
  • tB0c method t-butyloxycarbonyl method
  • Closo / Ig can relieve symptoms in renal disease model mice Because it can be used, it can be used as a therapeutic or prophylactic drug for kidney disease.
  • Closo ZIg can relieve the symptoms of cachexia disease model mice, so that it can be used as a therapeutic or preventive drug for cachexia.
  • Closo / Ig can restore the symptoms of osteoarthritis model mice, and can be used as a therapeutic or prophylactic agent for osteoarthritis.
  • compositions comprising the protein of the present invention, the therapeutic agent or prophylactic agent as the protein alone be administered can also be a certain force s, usually one is had the higher of allowed the protein pharmacological It is desirable to mix it with a carrier and provide it as a pharmaceutical preparation produced by any of the methods well-known in the art of pharmacy.
  • a sterile solution which is dissolved in an aqueous carrier such as water or an aqueous solution of salt, glycine, glucose, human albumin or the like is used.
  • pharmacologically acceptable additives such as buffering agents and tonicity agents to bring the formulation solution closer to physiological conditions, such as sodium acetate, sodium chloride, sodium lactate, potassium chloride, quencher Sodium acid or the like can also be added. It can also be lyophilized for storage and dissolved in an appropriate solvent before use.
  • the parenteral route for example, the subcutaneous, intramuscular, intravenous, or respiratory route is used.
  • the dose or frequency of administration varies depending on the desired therapeutic effect, administration method, treatment period, age, body weight, etc., and is usually 10 ⁇ g / kg to 20 mg / kg per day for an adult.
  • Closo ZI g For molecules that bind to and interact with the extracellular domain of Croso, Can be used in the same manner as antibodies against the molecule [Cell, 73, 447 (1993), Pro Natl. Acad. Sci. USA, 92, 1866 (1995)]. That is, when the immunoglobulin constant region of Closo ZI g is labeled with fluorescence, peroxidase, radioisotope, or the like, the Closo Ig can be easily detected using the label. Similarly to the antibody that recognizes, it is possible to detect the above molecule that binds to the Closo ZIg, or to isolate the cell using a cell sorter if the molecule is present on the cell surface.
  • the cell expressing the molecule to be bound is screened using Closo / Ig against a cell group into which the expressed cDNA library has been introduced, whereby the cloned ZIg is obtained. It is also possible to clone the cDNA of the molecule to which it binds. This method has the following advantages over the method using a closoprotein and an anti-closo antibody.
  • Labeled anti-immunoglobulin antibodies (FITC-labeled anti-human IgG antibodies, etc.) are commercially available and easily available.
  • an excess of the molecule in which the molecule is immobilized on beads or the like is added to the reaction solution in excess, and free closo ZIg present in the reaction solution is bound to the molecule in which the molecule is immobilized, and centrifugation is performed. Remove. After removal, it remains in the reaction solution.
  • the amount of the molecule bound to the labeled Closo / Ig is determined by measuring the existing labeled Closo ZIg by a detection method according to the label, such as radioactivity or coloring of a substrate that develops a color with an enzyme.
  • the immunocomplex of the immobilized Closo ZIg and the labeling molecule is separated from the solution by centrifugation or the like, and the amount of the labeling molecule bound to the antibody is measured by measuring the radioactivity.
  • the immobilized antibody against the immunoglobulin constant region used for Crosono Ig was used to separate the immunocomplex of Crosono Ig and the labeled molecule from the solution without immobilizing Closo ZIg. You can also.
  • Closo Ig of the present invention By immunizing Closo Ig of the present invention as an antigen, an antibody recognizing Closoprotein can be obtained.
  • Crosono Ig is used as an antigen, an antibody that recognizes the immunoglobulin portion of Closo ZIg is usually produced simultaneously in the serum of the immunized animal. Is prepared, and a monoclonal antibody recognizing the closoprotein is selected from among them.
  • the Closo ZIg of the present invention is administered subcutaneously, intravenously or intraperitoneally to a non-human mammal such as a heron, a goat, a rat, a mouse, a hamster and the like.
  • the closo 1 g of may be administered as it is force 5 ', Freund's complete adjuvant (Complete Freund' s Adjuvant), aluminum hydroxide gel, pertussis vaccine and the like, it forces s preferably is administered with a suitable adjuvant.
  • Freund's complete adjuvant Complete Freund' s Adjuvant
  • aluminum hydroxide gel aluminum hydroxide gel
  • pertussis vaccine and the like, it forces s preferably is administered with a suitable adjuvant.
  • the administration of the antigen is performed 3 to 10 times every 1 to 2 weeks after the first administration. After each dose Blood is collected from the fundus venous plexus on the 3rd to 7th days, and whether or not the serum reacts with the Closo ZIg used for immunization is determined according to an enzyme immunoassay (Antibodies-A Laboratory Manual, Cold Spring Harbor Laboratory, 1988). Check by measuring the antibody titer. A non-human mammal whose serum shows a sufficient antibody titer against the antigen used for immunization is used as a source of antibody-producing cells.
  • spleen cells As the antibody-producing cells, spleen cells, lymph nodes, and antibody-producing cells in peripheral blood, particularly splenocytes, are suitably used.
  • the hybridoma can be prepared by the following method.
  • the antibody-producing cells and myeloma cells are mixed, suspended in HAT medium (medium containing hypoxanthine, thymidine, and aminopterin in normal medium), and cultured for 7 to 14 days. After cultivation, a portion of the culture supernatant is removed, and those that react with the antigen but do not react with the protein containing no antigen are selected by enzyme immunoassay or the like. Next, single cloning is performed by the limiting dilution method, and those with a stable high antibody titer determined by the enzyme immunoassay are selected as monoclonal antibody-producing hybridomas.
  • HAT medium medium containing hypoxanthine, thymidine, and aminopterin in normal medium
  • the selected hybridomas are cultured, and the culture supernatant is used as the primary antibody, and the sample containing the closoprotein is subjected to stamping to detect the absorptive force of the same molecular weight as the kokusoprotein.
  • W098 / 29544 as a sample containing closoprotein
  • the culture supernatant of CHO cells into which the closoprotein produced by the method described in (1), for example, the human secretory closoprotein expression plasmid pYS111 has been introduced, can be used.o
  • Estane blotting can be performed according to the method described in Antibodies-A Laboratory Manual, Cold Spring Harbor Laboratory (1988).
  • Monoclonal antibodies can be obtained from a culture solution obtained by culturing hybridoma cells, or a liquid obtained by injecting hybridoma cells into the peritoneal cavity of an animal and causing the animal to undergo water tumor. Can be prepared by separating and purifying from
  • Methods for separating and purifying monoclonal antibodies include centrifugation, ammonium sulfate precipitation, caprylic acid precipitation, or chromatography using DEAE-Sepharose columns, anion exchange columns, protein A or G columns, or gel filtration columns. And the like can be used alone or in combination.
  • Closoproteins can be immunologically detected or quantified using the above-mentioned monoclonal antibodies recognizing closoproteins, as in the case of antibodies using liposomal proteins as antigens.
  • Examples of the method for immunological detection include an ELISA method using a microtiter plate, a fluorescent antibody method, a western blot method, and an immunohistological staining method.
  • FIG. 1 is a view showing the structures of brassmids pKANTEXKLL ⁇ 1 and pKANTEXKLL ⁇ 4 for expressing Closo / IgG animal cells.
  • Closo / I g G l is Kurosono 1 8 DNA encoding G 1 F c, closo I GG4 Ji DNA encoding Kurosono 12_Rei_4 F c, P M0 is the Moroni one murine leukemia virus is a promoter LTR, dhfr is dihydrofolate reductase gene, G418I or animal cells antibiotic G 418 resistance gene, Amp 1 "is a transformation marker in represents the antibiotic ampicillin resistance gene in the form transformants marker one in E. coli.
  • Figure 2 shows the results of SDS-PAGE of purified Closo ⁇ IgG 1 (: and Closo 1304 Fc. The results under non-reducing conditions are shown in lanes 1 and 2, and the results under reducing conditions. The results are shown in lanes 3 and 4. Lanes 1 and 3 show the results with Closo / IgG1Fc, and lanes 2 and 4 show the results with Closo ZlgG4Fc, respectively. Indicates the molecular weight of the protein, the arrow on the left shows the value of each molecular weight (kDa), and the arrow on the right shows the position of each band of Closo IgGFc and the comparison with the marker. The approximate molecular weight (kDa) is shown.
  • FIG. 3 is a view showing the results of evaluation of purified Closono IgG1 Fc and Closo ZIgG4 Fc by the ELISA method.
  • the vertical axis indicates the absorbance at 415 nm, and the horizontal axis indicates the concentration of each Closo / IgGFC.
  • ⁇ shows the results of Kuroso ZIgG1Fc and the fist shows KuguchisoIgG4Fc.
  • FIG. 4 is a graph showing the results of ⁇ ⁇ stamp lotting of human secreted closoprotein using the culture supernatant of the hybridoma of mouse 2 and clone 5 as the primary antibody.
  • the band on the right side is a human secreted auxoprotein of about 70 kDa detected with a force of 5 kDa.
  • the lines and numbers on the left indicate the position of the band of the protein molecular weight marker and the value of the molecular weight (kDa).
  • FIG. 5 is a diagram showing the results of immunohistochemical staining of rat kidney using culture supernatants of hybridomas of mouse 2 and clone 5.
  • A shows the result at a magnification of 12.5 times with an optical microscope
  • B shows the result at a magnification of 50 times.
  • the part that looks dark (actually brown) is the part that has reacted with the force antibody.
  • FIG. 7 is a graph comparing organ weights (g) of thymus, spleen and testis of Closo mice 7 weeks after administration of Crosono IgG 1 Fc with the control group.
  • the black bar indicates the average organ weight of the Croso IgG 1 Fc-administered group (4 animals), and the shaded bar indicates the average organ weight of the PBS-administered control group (6 animals).
  • PBS-hKLCF were prepared.
  • the P vu II -Hind III linker encodes the C-terminus of human secreted closo (amino acid sequence 537-549) and the FLAG peptide (amino acid sequence Asp Tyr Lys Asp Asp Asp Asp Lys), the joint of P vu II- H ind III closo cDNA linker in one and F LAG B sp HI site solved? it exists.
  • the KpnI-SacII fragment obtained by digesting the amplified DNA with restriction enzymes JLnI and SacII, and the remaining portion of IgGIFC (part of CH2 and CH3) were The SacII-BamHI fragment of pKANTEX93, which encodes, was inserted between the KpnIZBamHI sites of the closing vector pBluescript SK (-), and human IgGlFC (hinge-CH2-CH3 ) Containing the plasmid pBS-Mrol ⁇ 1.
  • the IL-5 receptor chain is Up to C-terminal below SacI site Plastid, linker one peptide and human I g G 4 part of F c (to hinge hereinafter P ma CI site) S ac I site and E c 0 RI cytokines? Exists in double-stranded DNA (end encoding ) Was amplified.
  • SacI-EcoRI fragment obtained by cleaving the amplified DNA with restriction enzymes SacI and EcoRI was converted into a plasmid pAI297 (WO 97-10354) having human IL-5 receptor ⁇ chain cDNA.
  • human IL-5 receptor Ec0RI-SacI fragment containing the ⁇ - chain cDNA was prepared.
  • Plasmid pMKEX01 which encodes the human IL-5 receptor ⁇ chain human IgG4Fc chimeric polypeptide, was prepared by inserting between BamHI.
  • the Ec0RI-BamHI fragment containing the DNA encoding the closo "IgG4Fc of pBSKLL4 prepared in (4) is used to contain the animal cell expression vector portion of the plasmid pKANTEX93 ⁇ by coupling with 2_R I one B AMH I fragment, encoding the closo / I g G 4 F c of closo / / I GG4 the F c animal cell expression plasmid PKANTEXKLLy 4 of the work made.
  • pKANTEXKLL 7 4 The nucleotide sequence is shown in SEQ ID NO: 6.
  • Rat myeloma cell line ⁇ 2Z0 (ATCC No. CRL-1662) and Chinese hamster ovary epithelial cell line (3 ⁇ 40 / — () were used as host cells for the vector for expressing the Closo IgG Fc prepared in Example 1.
  • (: 1011 ⁇ 20644) (hereinafter referred to as DG 44)
  • YB 2Z0 was cultured in 10% fetal bovine serum (FBS) and 0.1% 2-mercapto for each cell culture.
  • FBS fetal bovine serum
  • DG44 is a modified Iscove's Dulbecco's medium supplemented with 10% FBS and 10% HT Sabment (Life 'Technologies). Iscove's modified Dulbecco's medium; I MDM) were cultured in 5% C 0 2 conditions with and grown.
  • pKANTEXKLLy4 was similarly introduced into two types of cells.
  • the electroporation was performed according to the method specified by Gene Pulser, except that the voltage was 0.2 kV, 250 / F for YB20, and 0.35 kV, 250 ⁇ F for DG44.
  • YB2 / 0 and DG44 were each suspended in 40 ml of the medium described in (1), and 200 / y1 was dispensed into a 96-well plate and cultured.
  • YB2 / 0 sucked out 100 u1 of the supernatant of 2001, added 1001 of YB20 medium supplemented with 1 mg Zm1G418, and cultured on day 3.
  • 100 1 1 of 200 1 was sucked, and 100 I of a medium for YB 20 supplemented with 0.1 mg of SmgZm 1 G418 was added.
  • the operation performed on the third day was repeated for another two days, followed by culturing.
  • Closo / IgFc secreted in the supernatant (pKANTEXKLL ⁇ 1 / YB2 / 0 16 cells, pKANTEXKLL 4 / YB2 / 0 33 cells, pKANTEXKLLa 1 / DG44 37 cells, pKANTEXKLL 74 / DG44 (26 cells), the cells were transferred to 24-well plates and cultivation was continued. [Quantification of Closo / Ig GF c by ELISA method]
  • An anti-human clonal monoclonal antibody KM207 (FERM BP—61197: WO988 / 29554) produced in mice using the N-terminal peptide of human closoprotein as an antigen at a concentration of 10 g / m1 Dissolve 50 ⁇ l of PBS (phosphate buffered saline) solution in a 96-well plate each time, and let it stand still in step 4 to immobilize KM 2 076 on the bottom of the hole. did. After discarding the solution, PBS100 ⁇ 1 containing 1% bovine serum albumin (BSA) was dispensed and allowed to stand at room temperature for 1 hour to perform blocking to prevent non-specific binding. Discard the solution and add 0.05% 6% After washing with 85 (PBS-Tween), 500 1 of the culture supernatant as a sample was added, and allowed to stand at room temperature for 1 hour to react with KM206.
  • PBS phosphate buffered saline
  • MTX methotrexate
  • the host YB2Z0 clone was cultured in a cell culture flask in 150 ml of GIT medium (Wako Pure Chemical Industries) until it became confluent. After becoming confluent, 0.5 mg of ZmlG418 and 200 nmolZ1MTX were added, and culture was continued for 4 days.
  • GIT medium Wako Pure Chemical Industries
  • 0.5 mg of ZmlG418 and 200 nmolZ1MTX were added, and culture was continued for 4 days.
  • For the clone of the host DG44 culture in the same medium (150 ml) for DG44 used in (1) until confluence, followed by addition of lmgZml G4 18 and 200 nmol 1 MTX to CH0. The medium was changed to -S-SFII medium (Life Technologies Inc.) and cultured for 4 days.
  • the medium after the culture of (3) was collected, and passed through a ProsepA column (Bioprocessing, Bioprocessing; volume: 1 m1) at a flow rate of 100 m1 / hour in step 4,
  • the secreted Closo gG F c was adsorbed in the medium.
  • Elution was carried out with 0.1 mol Zl glycine-HC1 (pH 3.0), and the eluate was collected by fractionating 1 ml each.
  • the fractionated eluate was immediately neutralized by adding 1 mo 1 Tris 50/1, and the amount of protein in the eluate was detected by absorbance at 280 nm. Collected pictures.
  • FIG. 3 shows the results of analyzing Closono IgG 1 (:, Closo 13 ⁇ 4 Fc) purified in (4) according to the ELISA method described in (2) of Example 2.
  • FIG. 3 shows the results of analyzing Closono IgG 1 (:, Closo 13 ⁇ 4 Fc) purified in (4) according to the ELISA method described in (2) of Example 2.
  • FIG. As shown in the figure, Closo IgG G Fc and Closo / Ig G4 Fc were detected by ELISA in a concentration-dependent manner, respectively.
  • ⁇ iKM2076 has been shown to have both a closo moiety recognized by the anti-human IgG antibody and a Fc moiety
  • Example 3 Closo ⁇ lg GFc as immunogen Preparation and evaluation of monoclonal antibodies recognizing closoprotein
  • mice Three mice were immunized once a week (total of 5 times) with Closo ZIgG1Fc (100y «g) purified in (2) of Example 2.
  • the preparation and selection of the hybridoma was carried out according to a conventional method described in Antibodies-A Laboratory Manual, Cold spring Harbor Laboratory (1988) and the like. That is, spleen cells of the immunized mouse were fused with mouse myeoma cells (P3-U1) to prepare a hybridoma.
  • the obtained hybridoma was cultured, and the culture supernatant was used as a sample to select and clone a hybridoma producing an antibody against Closo IgG 1 Fc by the ELISA assay.
  • the ELISA method uses a 96-well plate immobilized with 10 ⁇ g / ml of Closo IgG 1 Fc, and uses peroxidase-labeled anti-mouse immunoglobulin antibody as the primary antibody for detection. (DAK0) was used in the same manner as in Example 2, (4), ELI SA method.
  • an antibody that specifically recognizes the human secretory closoprotein expressed in CH0 cells was selected by Western blotting as follows. According to the method described in W09 8/2954, SDS-PAGE was performed using the culture supernatant 101 of CH0 cells expressing human secreted closoprotein, and PVDF (polyvinylidene difluoride) was obtained from the gel. C) Transferred to the membrane. After blocking for 1 hour with 1% BSA, the cells were reacted for 1 hour with the culture supernatant of each hybridoma selected above (containing 2 to 4 gZml of antibody).
  • FIG. 4 shows the results of Western blotting using one of the antibodies thus selected (mouse 2 and clone 5). Ri by the above method, the antibody force against human secreted Klotho protein of native type? To be able to effectively get the divide.
  • a 4-week-old SD rat female, weighing about 100 g, Nippon S.L.C. was anesthetized with 50 mg Zkg Nembutal, perfused and fixed with PLP (periodate-lysine-paraformaldehyde) fixative, and kidney was extracted.
  • the fixed tissue was washed with PBS containing 5% and 10% sucrose for 4 hours each, and then washed with PBS containing 15% sucrose at-° C and 4 ° C.
  • the washed tissue was embedded in a 0. CT compound (Sakura Fine Technical Co., Ltd.) and frozen with liquid nitrogen. Six-meter-thick frozen sections were prepared on a cryostat and mounted on silane-coated slides.
  • sample sections were treated with 0.3% hydrogen peroxide in methanol at room temperature for 10 minutes and washed with PBS.
  • Non-specific adsorption of antibodies was prevented by treating with ProteinBlock Serum Free (DAKO) at room temperature for 20 minutes.
  • DAKO ProteinBlock Serum Free
  • the sample section was incubated with the hybridoma culture supernatant of the antibody selected in (1) overnight at 4 After the reaction and washing with PBS, a biotinylated anti-mouse IgG1 goat antibody (Amersham Pharmacia Biotech) was reacted as a second antibody for 30 minutes at room temperature.
  • the sample slice was washed with PBS, reacted with Streptavidin-HRP conjugate Strept ABCompe 1 ex / HRP (DAKO) for 30 minutes at room temperature, and then washed with PBS.
  • Figure 5 shows the results of immunohistochemical staining using the culture supernatant of the hybridoma of one of the antibodies selected in (1) (mouse 2 and clone 5). In the tubules.
  • Example 4 Suppression of Senile Symptoms of Closo Mice by Administration of Closo / ⁇ IgG Fc Each animal was intraperitoneally administered at 10 ⁇ m. The administration was performed daily for 2 weeks from the start of administration, and once every 3 days thereafter.
  • PBS was administered to 6 one-week-old Kuroso mice at the same administration interval.
  • FIG. 6 shows the weight progress of the Kuroso mice in each group.
  • the weight gain was significantly higher in the group treated with Crosono IgG 1 Fc than in the control group, and the body weight increased with the age of the week, compared to the control group, which showed almost no weight gain. Was seen.
  • a cachexic model mouse was prepared by transplanting a tumor into a nude mouse and allowing it to survive as follows.
  • the human melanoma strain SEKI [In vitro culture of human cancer cells, Asakusa Shoten, Tokyo (1975)] was expanded according to the method of Iseki et al. [Jpn. J. Cancer Res., 86, 562 (1995)]. Thereafter, a 7-week-old male nude mouse BALB / c-nu / nu was subcutaneously implanted into the flank using an injection needle to form and maintain a tumor.
  • the formed tumor was excised, cut into 2 mm squares, and subcutaneously transplanted into the flank of a plurality of nude mice (7-week-old male, BALB / c-nu / nu) using a transplantation needle.
  • a transplantation needle 7-week-old male, BALB / c-nu / nu
  • 10 mice in which tumor engraftment was confirmed were selected as cachexia model mice, and subjected to a Closo / 1 gG1Fc administration test.
  • these cachexia model mice were compared with model mice with normal serum glucose concentrations (140 to 170 mg / dl) as the tumor grew. It is a mouse that has a severely reduced and cachectic trait.
  • the Crosono IgGI Fc purified in (4) of Example 2 was diluted with PBS to a concentration of 50 gZml, and this was diluted with a cachexia model mouse 1 week after cancer transplantation prepared in (1). Twenty-five Z animals were intraperitoneally administered to 5 mice at a time. The administration was performed twice a week every 3 to 4 days, and the administration period was 3 weeks.
  • PBS was administered to 5 cachexia model mice at the same administration interval and period.
  • a secretory closoprotein stable in blood is provided, and treatment or prevention of the onset of a disease involving the closo gene becomes possible.
  • SEQ ID NO: 1 Description of an artificial sequence: DNA encoding a chimeric protein of human secreted auxoprotein and a constant region of human IgG1 heavy chain (hinge-CH2-CH3)
  • SEQ ID NO: 2-artificial Sequence description Chimeric protein between human secreted auxoprotein and the constant region of human IgG1 heavy chain (hinge-CH2-CH3)
  • SEQ ID NO: 3 Description of Artificial Sequence: DNA encoding chimeric protein of human secreted closoprotein and constant region of human IgG4 heavy chain (hinge-CH2-CH3)
  • SEQ ID NO: 4 Description of artificial sequence: Chimeric protein of human secreted closoprotein and constant region of human IgG4 heavy chain (hinge-CH2-CH3)
  • SEQ ID NO: 5 Description of Artificial Sequence: DNA encoding chimeric protein of human secreted closoprotein and constant region of human IgG1 heavy chain (hinge-CH2-CH3)
  • SEQ ID NO: 6 Description of artificial sequence : DNA encoding a chimeric protein of human secretory closoprotein and the constant region of the human IgG4 heavy chain (hinge-CH2-CH3)
  • SEQ ID NO: 8-Description of artificial sequence antisense strand of linker designed to encode amino acids 537-549 of human secreted closoprotein and FLAG peptide
  • SEQ ID NO: 10 Description of artificial sequence: antisense strand of linker encoding the designed linker peptide
  • SEQ ID NO: 11 Description of artificial sequence: Sense primer designed to amplify DNA encoding part of the hinge and C H2 regions of IgG1 heavy chain
  • SEQ ID NO: 12 Description of artificial sequence: Copies hinge and part of CH2 region of IgG1 heavy chain Antisense primer designed to amplify the DNA to be sequenced.
  • SEQ ID NO: 13 Description of Artificial Sequence: Amplify DNA that codes for the hinge and part of the CH2 region of the IgG1 heavy chain. Sense primer designed as follows
  • SEQ ID NO: 14 Description of artificial sequence: Antisense primer designed to amplify DNA encoding the hinge and part of the CH2 region of IgG1 heavy chain
  • SEQ ID NO: 16 Description of Artificial Sequence: Designed to amplify DNA encoding part of the a- chain of the IL-5 receptor, and part of the hinge and CH2 regions of the IgG4 heavy chain Antisense primer
  • SEQ ID NO: 17 Description of Artificial Sequence: Designed to amplify DNA encoding a portion of the IL-5 receptor's ⁇ chain, and part of the hinge and CH2 regions of the IgG4 heavy chain.
  • Antisense primer Designed to amplify DNA encoding a portion of the IL-5 receptor's ⁇ chain, and part of the hinge and CH2 regions of the IgG4 heavy chain.
  • SEQ ID NO: 18 Description of Artificial Sequence: Designed to amplify DNA encoding part of the heavy chain of the IL-15 receptor, and part of the hinge and CH2 regions of the IgG4 heavy chain Antisense primer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne un nouveau polypeptide chimérique comprenant la protéine klotho et l'immunoglobuline liée à cette dernière, lequel qui reste stable dans le sang et peut être utilisé dans le traitement ou la prévention de maladies impliquant la participation du gène klotho. L'invention concerne également l'ADN codant pour ce polypeptide chimérique, un procédé de production de ce polypeptide, des médicaments préventifs/curatifs mettant en oeuvre ce polypeptide chimérique ou l'ADN codant pour celui-ci, un procédé de détection et de quantification d'une molécule interagissant avec la protéine klotho, ainsi qu'un procédé de clonage d'un gène codant pour une protéine interagissant avec la protéine klotho.
PCT/JP1999/006152 1998-11-05 1999-11-05 Nouveau popypeptide chimerique WO2000027885A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU10772/00A AU1077200A (en) 1998-11-05 1999-11-05 Novel chimeric polypeptide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP10/314153 1998-11-05
JP31415398 1998-11-05

Publications (1)

Publication Number Publication Date
WO2000027885A1 true WO2000027885A1 (fr) 2000-05-18

Family

ID=18049882

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1999/006152 WO2000027885A1 (fr) 1998-11-05 1999-11-05 Nouveau popypeptide chimerique

Country Status (1)

Country Link
WO (1) WO2000027885A1 (fr)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2316951A1 (fr) * 2001-01-17 2011-05-04 Trubion Pharmaceuticals, Inc. Proteines de fusion d'immunoglobuline de domaine de liaison
US8106161B2 (en) 2001-01-17 2012-01-31 Emergent Product Development Seattle, Llc Binding domain-immunoglobulin fusion proteins
US8147835B2 (en) 2001-01-17 2012-04-03 Emergent Product Development Seattle, Llc Binding domain-immunoglobulin fusion proteins
US20120172314A1 (en) * 2007-05-08 2012-07-05 Tel Hashomer Medical Research Infrastructure And Services Ltd. Klotho Protein and Related Compounds for the Treatment and Diagnosis of Cancer
US20120178699A1 (en) * 2007-05-08 2012-07-12 Tel Hashomer Medical Research Infrastructure And Services Ltd. Klotho protein and related compounds for the treatment and diagnosis of cancer
US8324160B2 (en) 2009-06-17 2012-12-04 Amgen Inc. Chimeric polypeptides and uses thereof
US8333966B2 (en) 2008-04-11 2012-12-18 Emergent Product Development Seattle, Llc CD37 immunotherapeutics and uses thereof
US8361963B2 (en) 2008-06-04 2013-01-29 Amgen Inc. Uses of FGF21 polypeptides comprising two or more mutations
US8372952B2 (en) 2009-12-02 2013-02-12 Amgen Inc. Binding proteins that bind to human FGFR1C, human β-klotho and both human FGFR1C and human β-klotho
US8409577B2 (en) 2006-06-12 2013-04-02 Emergent Product Development Seattle, Llc Single chain multivalent binding proteins with effector function
US8795985B2 (en) 2009-05-05 2014-08-05 Amgen Inc. FGF 21 polypeptides comprising two or more mutations and uses thereof
US9279013B2 (en) 2008-10-10 2016-03-08 Amgen Inc. FGF-21 mutants comprising polyethylene glycol and uses thereof
US9284378B2 (en) 2009-12-07 2016-03-15 Shaw-Fen Sylvia Hu Human antigen binding proteins that bind β-Klotho, FGF receptors and complexes thereof
US9493530B2 (en) 2009-05-05 2016-11-15 Amgen Inc. FGF21 mutants comprising a mutation at position 98, 171 and/or 180
US10143748B2 (en) 2005-07-25 2018-12-04 Aptevo Research And Development Llc B-cell reduction using CD37-specific and CD20-specific binding molecules
CN109219663A (zh) * 2016-06-02 2019-01-15 克洛索治疗有限公司 治疗性重组klotho蛋白及其组合物和方法
CN109251896A (zh) * 2018-08-13 2019-01-22 中山大学 一株高表达hKLs-his蛋白的细胞株及其制备方法和应用
CN109996555A (zh) * 2016-11-22 2019-07-09 克洛索治疗有限公司 新颖重组klotho蛋白及其组合物和方法
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991008298A2 (fr) * 1989-11-22 1991-06-13 Genentech, Inc. Proteines de fusion comprenant une proteine de fixation de ligand et une proteine plasmatique stable
EP0533006A1 (fr) * 1991-09-18 1993-03-24 F.Hoffmann-La Roche & Co. Aktiengesellschaft Chimères constituées du récepteur de l'interleukine 5 et de polypeptides d'immunoglobulines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991008298A2 (fr) * 1989-11-22 1991-06-13 Genentech, Inc. Proteines de fusion comprenant une proteine de fixation de ligand et une proteine plasmatique stable
EP0533006A1 (fr) * 1991-09-18 1993-03-24 F.Hoffmann-La Roche & Co. Aktiengesellschaft Chimères constituées du récepteur de l'interleukine 5 et de polypeptides d'immunoglobulines

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BYRN R.A. ET AL.: "Biological properties of a CD4 immunoadhesin", NATURE,, vol. 344, 12 April 1990 (1990-04-12), pages 667 - 670, XP002935538 *
CAPON D.J. ET AL.: "Designing CD4 immunoadhesins for AIDS therapy", NATURE,, vol. 337, 9 February 1989 (1989-02-09), pages 525 - 531, XP002935537 *
KURO-O.M. ET AL.: "Mutation of the mouse klotho gene leads to a syndrome resembling ageing", NATURE,, vol. 390, 6 November 1997 (1997-11-06), pages 45 - 51, XP002935535 *
KURSCHNER C. ET AL.: "IFN-gamma receptor-Ig fusion proteins half-life, immunogenicity and in vivo activity", THE JOURNAL OF IMMUNOLOGY,, vol. 149, no. 12, 1992, pages 4096 - 4100, XP002935536 *
MATSUMURA Y. ET AL.: "Identification of the human klotho gene and its two transcripts encoding membrane and secreted klotho protein", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS,, vol. 242, no. 3, 1998, pages 626 - 630, XP002935534 *

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9005612B2 (en) 2001-01-17 2015-04-14 Emergent Product Development Seattle, Llc Binding domain-immunoglobulin fusion proteins
US8106161B2 (en) 2001-01-17 2012-01-31 Emergent Product Development Seattle, Llc Binding domain-immunoglobulin fusion proteins
US8147835B2 (en) 2001-01-17 2012-04-03 Emergent Product Development Seattle, Llc Binding domain-immunoglobulin fusion proteins
US8188237B2 (en) 2001-01-17 2012-05-29 Emergent Product Development Seattle, Llc Binding domain-immunoglobulin fusion proteins
US8197810B2 (en) 2001-01-17 2012-06-12 Emergent Product Development Seattle, Llc Binding domain-immunoglobulin fusion proteins
US8853366B2 (en) 2001-01-17 2014-10-07 Emergent Product Development Seattle, Llc Binding domain-immunoglobulin fusion proteins
EP2316951A1 (fr) * 2001-01-17 2011-05-04 Trubion Pharmaceuticals, Inc. Proteines de fusion d'immunoglobuline de domaine de liaison
US10143748B2 (en) 2005-07-25 2018-12-04 Aptevo Research And Development Llc B-cell reduction using CD37-specific and CD20-specific binding molecules
US10307481B2 (en) 2005-07-25 2019-06-04 Aptevo Research And Development Llc CD37 immunotherapeutics and uses thereof
US8409577B2 (en) 2006-06-12 2013-04-02 Emergent Product Development Seattle, Llc Single chain multivalent binding proteins with effector function
US20120178699A1 (en) * 2007-05-08 2012-07-12 Tel Hashomer Medical Research Infrastructure And Services Ltd. Klotho protein and related compounds for the treatment and diagnosis of cancer
US9987326B2 (en) * 2007-05-08 2018-06-05 Tel Hashomer Medical Research Infrastructure And Services Ltd. Klotho protein and related compounds for the treatment and diagnosis of cancer
US10555963B2 (en) * 2007-05-08 2020-02-11 Tel Hashomer Medical Research Infrastructure And Services Ltd. Klotho protein and related compounds for the treatment and diagnosis of cancer
US20120172314A1 (en) * 2007-05-08 2012-07-05 Tel Hashomer Medical Research Infrastructure And Services Ltd. Klotho Protein and Related Compounds for the Treatment and Diagnosis of Cancer
US9101609B2 (en) 2008-04-11 2015-08-11 Emergent Product Development Seattle, Llc CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US8333966B2 (en) 2008-04-11 2012-12-18 Emergent Product Development Seattle, Llc CD37 immunotherapeutics and uses thereof
US8642546B2 (en) 2008-06-04 2014-02-04 Amgen Inc. FGF21 mutant fusion polypeptides and uses thereof
US8410051B2 (en) 2008-06-04 2013-04-02 Amgen Inc. FGF21 mutants and uses thereof
US11072640B2 (en) 2008-06-04 2021-07-27 Amgen Inc. Methods of treating non-alcoholic steatohepatitis using FGF21 mutants
US8361963B2 (en) 2008-06-04 2013-01-29 Amgen Inc. Uses of FGF21 polypeptides comprising two or more mutations
US9273106B2 (en) 2008-06-04 2016-03-01 Amgen Inc. FGF mutants with reduced proteolysis and aggregation
US11840558B2 (en) 2008-06-04 2023-12-12 Amgen Inc. Methods of treating non-alcoholic steatohepatitis using FGF21 mutants
US10011642B2 (en) 2008-06-04 2018-07-03 Amgen Inc. Methods of treating of diabetes and obesity using FGF21 mutants
US9279013B2 (en) 2008-10-10 2016-03-08 Amgen Inc. FGF-21 mutants comprising polyethylene glycol and uses thereof
US8795985B2 (en) 2009-05-05 2014-08-05 Amgen Inc. FGF 21 polypeptides comprising two or more mutations and uses thereof
US9493530B2 (en) 2009-05-05 2016-11-15 Amgen Inc. FGF21 mutants comprising a mutation at position 98, 171 and/or 180
US8835385B2 (en) 2009-05-05 2014-09-16 Amgen Inc. FGF21 polypeptides comprising two or more mutations and uses thereof
US8324160B2 (en) 2009-06-17 2012-12-04 Amgen Inc. Chimeric polypeptides and uses thereof
US8372952B2 (en) 2009-12-02 2013-02-12 Amgen Inc. Binding proteins that bind to human FGFR1C, human β-klotho and both human FGFR1C and human β-klotho
US9493577B2 (en) 2009-12-07 2016-11-15 Amgen Inc. Human antigen binding proteins that bind β-klotho, FGF receptors and complexes thereof
US10570205B2 (en) 2009-12-07 2020-02-25 Amgen, Inc. Human antigen binding proteins that bind β-Klotho, FGF receptors and complexes thereof
US9284378B2 (en) 2009-12-07 2016-03-15 Shaw-Fen Sylvia Hu Human antigen binding proteins that bind β-Klotho, FGF receptors and complexes thereof
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides
CN109219663A (zh) * 2016-06-02 2019-01-15 克洛索治疗有限公司 治疗性重组klotho蛋白及其组合物和方法
EP3464608A4 (fr) * 2016-06-02 2020-01-29 Klotho Therapeutics, Inc. Protéines klotho recombinées thérapeutiques et compositions et méthodes comprenant celles-ci
KR20190015711A (ko) * 2016-06-02 2019-02-14 클로토 테라퓨틱스, 아이엔씨. 치료학적 재조합 클로토 단백질 및 이를 수반하는 조성물 및 방법
JP2019526272A (ja) * 2016-06-02 2019-09-19 クロトー セラピューティクス インコーポレイテッドＫｌｏｔｈｏ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 治療用組換えクロトータンパク質ならびにそれを含む組成物および方法
AU2017272349B2 (en) * 2016-06-02 2022-12-01 Klotho Therapeutics, Inc. Therapeutic recombinant klotho proteins and compositions and methods involving the same
KR102570250B1 (ko) * 2016-06-02 2023-08-29 클로토 테라퓨틱스, 아이엔씨. 치료학적 재조합 클로토 단백질 및 이를 수반하는 조성물 및 방법
JP2019535740A (ja) * 2016-11-22 2019-12-12 クロトー セラピューティクス インコーポレイテッドＫｌｏｔｈｏ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 新規な組換えクロトータンパク質ならびにそれを含む組成物および方法
EP3551212A4 (fr) * 2016-11-22 2020-11-04 Klotho Therapeutics, Inc. Nouvelles protéines klotho recombinées et compositions et méthodes les comprenant
JP7244923B2 (ja) 2016-11-22 2023-03-23 クロトー セラピューティクス インコーポレイテッド 新規な組換えクロトータンパク質ならびにそれを含む組成物
AU2017363321B2 (en) * 2016-11-22 2023-09-28 Klotho Therapeutics, Inc. Novel recombinant Klotho proteins and compositions and methods involving the same
CN109996555A (zh) * 2016-11-22 2019-07-09 克洛索治疗有限公司 新颖重组klotho蛋白及其组合物和方法
US11932676B2 (en) 2016-11-22 2024-03-19 Klotho Therapeutics, Inc. Recombinant klotho proteins and compositions and methods involving same
CN109251896A (zh) * 2018-08-13 2019-01-22 中山大学 一株高表达hKLs-his蛋白的细胞株及其制备方法和应用

Similar Documents

Publication Publication Date Title
WO2000027885A1 (fr) Nouveau popypeptide chimerique
US8492526B2 (en) Effector function enhanced recombinant antibody composition
JP3946256B2 (ja) ヒトインターロイキン５受容体α鎖に対する抗体
WO2007011041A1 (fr) Composition d'anticorps génétiquement modifié
CN102459603A (zh) 岩藻糖基化缺陷型细胞
WO2005035577A1 (fr) Compositions d'anticorps se liant specifiquement au ganglioside gd3
WO2018188612A1 (fr) Anticorps bispécifique pouvant être combiné avec cd19 humain ou cd20 humain et cd3 humain, et applications associées
JPWO2008090960A1 (ja) ガングリオシドｇｍ２に特異的に結合する遺伝子組換え抗体組成物
WO2003085102A1 (fr) Cellule avec inhibition ou suppression de l'activite de la proteine participant au transport du gdp-fucose
US8003098B2 (en) Methods for damaging cells using effector functions of anti-EphA4 antibodies
WO2007142277A1 (fr) Anticorps monoclonal capable de se lier au facteur de croissance de type facteur de croissance épidermique se liant à l'héparine
WO2000035956A1 (fr) Anticorps monoclonal anti-vegf humain
US6962984B2 (en) IgA nephropathy-related DNA
WO2007099988A1 (fr) mutant de α-1,6-FUCOSYLTRANSFERASE et son utilisation
WO2002090546A1 (fr) Polypeptide servant de marqueur angiogenique et son adn
CN112996811B (zh) 双特异性蛋白
AU754278B2 (en) Monoclonal antibody against human telomerase catalytic subunit
EP1335024A1 (fr) Anticorps inhibant l'activite vplf
WO2000018805A1 (fr) Nouveaux anticorps, medicaments les contenant et methodes de criblage de composes par utilisation desdits anticorps
JP2001231578A (ja) Ｉｌ−１ファミリーに属する蛋白質
WO2005035578A1 (fr) Composition d'anticorps soulignant specifiquement au ganglioside gm2
US20040081972A1 (en) Novel physiologically active peptide and use thereof
JPWO2005035583A1 (ja) Ｉｌ−５受容体に特異的に結合する抗体組成物
JPWO2005035582A1 (ja) Ｃｃｒ４に特異的に結合する抗体組成物
CA2329683C (fr) Adn relie a la nephropathie iga

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 10772

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A1

Designated state(s): AU BG BR CA CN CZ HU ID IL IN JP KR MX NO NZ PL RO SG SI SK UA US VN ZA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 581062

Kind code of ref document: A

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase